Glioma Clinical Trial
Official title:
Multimodal Imaging of Hypoxia in Gliomas
The imaging of cerebral oxygenation is an extremely important tool in understanding the
pathophysiology of the tumor and for adaptation of therapies according to hypoxia. Currently,
imaging of cerebral oxygenation is mainly performed by the use of Positron Emission
Tomography (PET). Thus, the investigators have been able to show that the FMISO radiotracer
can reveal tumor hypoxia (HypOnco study, promotor: Caen University Hospital, main
investigator: J.S. Guillamo). After injection of the radiotracer, increased uptake is
observed in the regions for which the tissue oxygen pressure is less than 10 mmHg (the
healthy brain with a tissue oxygen pressure (ptO2) ≈ 40mmHg).
Although PET is a reference methodology, it is not widely practiced mainly because of
radioactive sources. Magnetic Resonance Imaging (MRI) would bypass the previously mentioned
PET limitations. The investigators have recently shown that a measure of local oxygen
saturation could be obtained by MRI.
This methodology has also been implemented at a clinical scale on lower field MRI magnets,
but its formal validation in a clinical situation remains to be demonstrated with respect to
FMISO.
The major advantage of this methodology is that MRI is already performed in routine practice
for patients. Measuring tissue oxygenation with MRI (SatO2-MRI) would not add additional
examination for the patient. In addition, MRI is a non-ionizing methodology with a very good
spatial resolution compared to PET, this should help to better understand intratumoral
heterogeneity. Similarly, in preclinical studies, the investigators have shown in a context
of mild hypoxia that SatO2-MRI may be more sensitive than PET.
The investigators propose a study to compare in patients with glial tumors, images obtained
by 3 Tesla MRI of SatO2-MRI to the hypoxia maps obtained by FMISO PET. These imaging studies
will be confronted with studies carried out in immunohistochemistry on biopsies / resection
allowing to reveal and to quantify by image analysis the expression of the factors induced by
hypoxia (HIF1, HIF2).
This study should include 20 patients with glioma (15 high-grade patients and 5 low-grade
patients) in pre-surgery. The aim is to show that SatO2-MRI is a relevant methodology (in
terms of sensitivity, specificity) for assessing intratumoral oxygenation in a context of
brain tumors. This fits perfectly into an era of personalized medicine where functional
imaging finds its meaning.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04539574 -
An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors
|
N/A | |
| Enrolling by invitation |
NCT04461002 -
Evaluation of the Correlation Between Molecular Phenotype and Radiological Signature (by PET-scanner and MRI) of Incident WHO II and III Grade Gliomas.
|
||
| Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
| Completed |
NCT03242824 -
The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma
|
Phase 2 | |
| Recruiting |
NCT04186832 -
Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy
|
N/A | |
| Completed |
NCT00424554 -
Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)
|
Phase 2 | |
| Recruiting |
NCT05968053 -
Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
|
||
| Not yet recruiting |
NCT04550663 -
NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors
|
Phase 1 | |
| Completed |
NCT02805179 -
A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma
|
Phase 2 | |
| Terminated |
NCT04556929 -
Enhanced Detection in Glioma Excision
|
N/A | |
| Not yet recruiting |
NCT06408428 -
Glioma Intraoperative MicroElectroCorticoGraphy
|
N/A | |
| Recruiting |
NCT06043232 -
MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas
|
||
| Not yet recruiting |
NCT06043765 -
Reducing Cognitive Impairment in Glioma With Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training
|
N/A | |
| Not yet recruiting |
NCT05025969 -
Evaluation of the Incidence of NTRK Gene Fusion in Adult Brain Tumours
|
||
| Completed |
NCT02978261 -
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas
|
Phase 1 | |
| Terminated |
NCT01502605 -
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
|
Phase 1 | |
| Completed |
NCT01836536 -
Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients
|
N/A | |
| Completed |
NCT01479686 -
iMRI Guided Resection in Cerebral Glioma Surgery
|
Phase 3 | |
| Completed |
NCT01212731 -
Skull Base and Low Grade Glioma Neurocognitive Magnetic Resonance Imaging (MRI) Study
|
||
| Withdrawn |
NCT00985036 -
Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients
|
N/A |